GLP-1 Medications and Fatty Liver: What the Research Shows for MASLD and MASH

*This article is for informational and educational purposes only. It is not medical advice. Compounded semaglutide and tirzepatide are not FDA-approved medications for fatty liver disease or MASH. The clinical research cited here used FDA-approved branded formulations; results may not apply to compounded products. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*

---

Fatty liver disease has quietly become one of the most common liver conditions in the world. An estimated one in four adults globally carries some degree of excess fat in their liver, and the majority have no idea until a routine blood panel or imaging scan turns up an unexpected finding. For decades, the only proven treatment was sustained lifestyle change: lose weight, eat better, move more. Good advice that most people find very hard to act on long term.

That picture is shifting. Two major clinical trials, one for semaglutide and one for tirzepatide, have now reported striking results for fatty liver disease in the New England Journal of Medicine. GLP-1 receptor agonists appear to reduce liver fat, resolve active liver inflammation, and in some cases improve fibrosis, the scarring that makes fatty liver disease serious.

This article explains what fatty liver disease actually is, how GLP-1 medications appear to work on liver tissue, and what the clinical trial data show for both semaglutide and tirzepatide.

---

Understanding MASLD and MASH

The terminology around fatty liver disease was updated in 2023 when major liver disease organizations agreed on new names that better reflect the underlying biology.

NAFLD (non-alcoholic fatty liver disease) is now called MASLD (metabolic dysfunction-associated steatotic liver disease). NASH (non-alcoholic steatohepatitis) is now called MASH (metabolic dysfunction-associated steatohepatitis). You will encounter both sets of terms depending on when a study was published.

The name change matters because it makes explicit what the science has long established: this is a metabolic condition tied to obesity, insulin resistance, elevated triglycerides, and type 2 diabetes. It is not simply about what you eat or drink. It is about how your metabolism processes and stores fat.

Here is how the condition progresses:

• MASLD (simple steatosis): Fat accumulates in liver cells. Most people feel nothing and have no symptoms. Liver enzymes may be mildly elevated on bloodwork.
• MASH (steatohepatitis): Fat accumulation is accompanied by inflammation and liver cell injury. This is more serious because it can cause fibrosis.
• Fibrosis: Repeated inflammation leads to scar tissue forming in the liver. Scar tissue does not function like healthy liver tissue.
• Cirrhosis: Advanced fibrosis where normal liver architecture is replaced by scarring. Liver failure and liver cancer risk rise substantially.

MASH has become one of the leading causes of liver transplants in the United States. The metabolic connection to obesity is direct: as obesity rates have risen, so has MASH.

---

Why GLP-1 Medications Target the Liver

GLP-1 receptor agonists were developed for blood sugar management in type 2 diabetes and later for weight loss. Their effect on fatty liver disease appears to be a meaningful secondary benefit, driven by several overlapping mechanisms.

Weight loss reduces liver fat directly. The liver is one of the first places the body deposits and draws from fat stores. When significant weight is lost, liver fat decreases substantially. Since GLP-1 medications produce the most consistent and substantial weight loss seen in clinical pharmacology outside of bariatric surgery, this effect on hepatic fat is largely expected.

Insulin sensitization reduces hepatic lipogenesis. One of the central drivers of MASLD is insulin resistance, which signals the liver to produce and accumulate more fat (a process called de novo lipogenesis). GLP-1 receptor agonists improve insulin sensitivity in the liver and peripheral tissues, reducing this fat-generating signal.

Direct hepatic receptor activity. GLP-1 receptors are expressed in the liver itself. Preclinical research suggests direct anti-inflammatory and anti-fibrotic effects at the liver level, independent of weight loss.

Reduced visceral adiposity. The fat stored deep in the abdomen around the organs (visceral fat) releases inflammatory signals that drive liver inflammation. GLP-1 medications preferentially reduce visceral fat, which reduces this inflammatory burden on the liver.

---

Semaglutide: The ESSENCE Trial

The most definitive data for semaglutide comes from the ESSENCE trial, a Phase 3 study published in the *New England Journal of Medicine* in 2025 (Sanyal AJ et al., PMID 40305708).

ESSENCE enrolled 800 adults with biopsy-confirmed MASH and moderate or advanced liver fibrosis (stage F2 or F3). Participants were randomized to receive subcutaneous semaglutide 2.4 mg weekly or placebo for 72 weeks, after which all participants received semaglutide for an additional 24 weeks.

The results at 72 weeks were clinically striking:

• Resolution of steatohepatitis without worsening fibrosis: 62.9% in the semaglutide group vs. 34.3% in the placebo group (a difference of 28.7 percentage points).
• Reduction in liver fibrosis without worsening steatohepatitis: 36.8% vs. 22.4% (a 14.4 percentage point difference).
• Combined resolution of MASH and improvement in fibrosis: 32.7% vs. 16.1%.
• Weight loss: -10.5% with semaglutide vs. -2.0% with placebo.

More than 60% of participants on semaglutide achieved resolution of MASH. That is a substantial number given that no pharmacological treatment for MASH had previously cleared the bar in a Phase 3 trial.

The fibrosis results are particularly meaningful clinically. Scar tissue in the liver does not easily reverse. The fact that more than one in three patients on semaglutide showed fibrosis improvement suggests an effect that goes beyond weight loss alone.

Adverse events were primarily gastrointestinal (nausea, vomiting, diarrhea), consistent with the known profile of GLP-1 receptor agonists. Most were mild to moderate and occurred early in treatment.

For a deeper review of semaglutide's fatty liver data specifically, see our article on [semaglutide and fatty liver disease](/resources/semaglutide-fatty-liver-nafld-mash-research).

---

Tirzepatide: The SYNERGY-NASH Trial

Tirzepatide takes a different pharmacological approach than semaglutide. It is a dual agonist of both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP activity adds a distinct metabolic signal that may amplify the effects on body weight and liver fat.

The SYNERGY-NASH trial, published in the *New England Journal of Medicine* in 2024 (Loomba R et al., PMID 38856224), was a Phase 2 study enrolling 190 adults with biopsy-confirmed MASH and moderate or severe fibrosis (stage F2 or F3).

Participants received subcutaneous tirzepatide at 5 mg, 10 mg, or 15 mg weekly, or placebo, for 52 weeks.

Results for resolution of MASH without worsening fibrosis were dose-dependent and substantially higher than placebo across all dose levels:

• Placebo: 10%
• Tirzepatide 5 mg: 44%
• Tirzepatide 10 mg: 56%
• Tirzepatide 15 mg: 62%

For fibrosis improvement (at least one stage better without worsening MASH), results were:

• Placebo: 30%
• Tirzepatide 5 mg: 55%
• Tirzepatide 10 mg: 51%
• Tirzepatide 15 mg: 51%

The fibrosis improvement rates are notable. Roughly half of tirzepatide participants across all three dose levels showed meaningful fibrosis regression, compared to less than a third on placebo.

Because SYNERGY-NASH was a Phase 2 trial, larger Phase 3 data in a broader population are still needed before conclusions can be generalized. But the magnitude of effect is consistent with what was later confirmed in the semaglutide Phase 3 trial.

For a detailed breakdown of the tirzepatide liver data, see our article on [tirzepatide and fatty liver disease](/resources/tirzepatide-fatty-liver-masld-mash-research).

---

What a Meta-Analysis Adds

Beyond the landmark trials, a 2025 meta-analysis published in the *Journal of Clinical Endocrinology and Metabolism* (Wang Y et al., PMID 40489581) pooled data from 25 randomized controlled trials covering 2,600 patients across multiple GLP-1 receptor agonists, including liraglutide, semaglutide, tirzepatide, and newer agents.

Key findings from that pooled analysis:

• GLP-1 receptor agonist treatment over a median of 24 weeks reduced liver fat content by an average of 5.21 percentage points.
• Statistically significant improvements were seen in histological steatosis, hepatocellular ballooning, and lobular inflammation.
• Fibrosis improvement did not reach statistical significance in the pooled analysis, though the larger individual trials (ESSENCE, SYNERGY-NASH) showed fibrosis benefits.
• Liver enzymes (ALT, AST, and GGT) all decreased significantly compared to control.
• No drug-related liver adverse effects were observed across any of the included agents.

The meta-analysis reinforces that the benefits seen in ESSENCE and SYNERGY-NASH are not unique to single molecules. The GLP-1 receptor agonist class as a whole appears to consistently improve the metabolic environment for fatty liver disease.

---

Who This Research Applies To

The clinical trials enrolled specific populations: adults with biopsy-confirmed MASH and moderate to advanced fibrosis (stage F2 or F3). These are people with relatively serious liver disease, not just elevated liver enzymes or mild fat accumulation.

Whether the same magnitude of benefit applies across the full spectrum of MASLD, from simple steatosis to early MASH, remains an active research question. The plausible mechanisms (weight loss, insulin sensitization, direct liver effects) suggest benefit at earlier stages as well, but the clinical trial evidence is strongest for those with confirmed MASH and fibrosis.

It is also worth noting that none of these trials were conducted using compounded semaglutide or tirzepatide. The research used FDA-approved formulations at specific doses under controlled conditions. Extrapolating these results to compounded products requires caution.

---

What to Discuss With Your Provider

If you have fatty liver disease or have been told you have elevated liver enzymes alongside metabolic conditions like obesity, type 2 diabetes, or insulin resistance, these findings are worth discussing with your healthcare team.

Questions worth raising include:

• Has my liver health been assessed with imaging or bloodwork recently?
• Do I have MASLD or MASH, and if so, what stage?
• Would a GLP-1 medication be appropriate given my overall metabolic profile?
• What monitoring makes sense if I do start treatment?

GLP-1 medications are not currently FDA-approved for MASLD or MASH treatment specifically. They are approved for type 2 diabetes and obesity. However, the intersection of these conditions is real: most people with MASH also have metabolic risk factors where GLP-1 therapy may already be indicated.

---

The Bottom Line

Two Phase 2 and Phase 3 trials in the New England Journal of Medicine now show that both semaglutide and tirzepatide produce significant improvements in liver histology in people with MASH and significant fibrosis. Resolution rates above 60% for steatohepatitis, and fibrosis improvement in roughly a third to half of participants, represent a meaningful shift in what is possible for a condition that previously had no effective pharmacological treatment.

The metabolic connection between obesity and fatty liver disease means these medications address the root cause rather than just managing symptoms. That mechanistic alignment, combined with the now-robust clinical evidence, makes this one of the more compelling areas of GLP-1 research.

*This is not medical advice. Compounded semaglutide and tirzepatide are not FDA-approved. Consult your licensed healthcare provider to understand whether GLP-1 therapy is appropriate for your specific situation.*

---

References

1. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. *N Engl J Med*. 2025;392(21):2089-2099. PMID: 40305708

1. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. *N Engl J Med*. 2024;391(4):299-310. PMID: 38856224

1. Wang Y, et al. Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis. *J Clin Endocrinol Metab*. 2025. PMID: 40489581